Telephone
61.03.9215.9215
Address
Level 6 2125 Dandenong Road Clayton, Victoria (VIC) 3168
Description
Sigma Healthcare Ltd. engages in the manufacture and distribution of pharmaceutical products through pharmacy, grocery channels, and private labels. The firm's activities include wholesale distribution of pharmaceutical goods and medical consumables to community pharmacies, including the provision of retail support services to the branded network of pharmacy members, dose administration aid services, technology and data analytics solutions to the customers. The company was founded on July 2, 1999 and is headquartered in Rowville, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.55 - 0.88
Trade Value (12mth)
AU$342,712.00
1 week
2.14%
1 month
7.52%
YTD
18.18%
1 year
14.4%
All time high
2.1614
EPS 3 yr Growth
N/A
EBITDA Margin
N/A
Operating Cashflow
N/A
Free Cash Flow Return
N/A
ROIC
N/A
Interest Coverage
N/A
Quick Ratio
N/A
Shares on Issue (Fully Dilluted)
1021m
HALO Sector
Healthcare
Next Company Report Date
21-Mar-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.05
Date | Announcements |
---|---|
31 March 17 |
Sigma Pharmaceuticals Limited - Notice of Annual General Meeting/Proxy Form (SIP-AU)
×
Sigma Pharmaceuticals Limited - Notice of Annual General Meeting/Proxy Form (SIP-AU) |
31 March 10 |
Full Year Results Presentation (SIP-AU)
×
Full Year Results Presentation (SIP-AU) |
31 August 23 |
Chemist Warehouse Supply Agreement signed
×
Chemist Warehouse Supply Agreement signed |
30 June 22 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
30 June 22 |
Change in substantial holding from MQG
×
Change in substantial holding from MQG |
30 June 22 |
Change in substantial holding
×
Change in substantial holding |
30 June 22 |
Change in substantial holding - HMC Capital Partners
×
Change in substantial holding - HMC Capital Partners |
30 December 22 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
29 September 10 |
Sigma 2010 Half Year Results Presentation (SIP-AU)
×
Sigma 2010 Half Year Results Presentation (SIP-AU) |
29 November 22 |
Sigma secures refinancing of Debt facility
×
Sigma secures refinancing of Debt facility |
29 November 11 |
Sigma Pharmaceuticals Limited - Investor Update Presentation (SIP-AU)
×
Sigma Pharmaceuticals Limited - Investor Update Presentation (SIP-AU) |
29 March 22 |
Appendix 4E & Full Year Financial Report
×
Appendix 4E & Full Year Financial Report |
29 March 22 |
Sigma Full Year 2021/2022 ASX Release
×
Sigma Full Year 2021/2022 ASX Release |
29 March 22 |
Sigma Full Year 2021/22 Results Presentation
×
Sigma Full Year 2021/22 Results Presentation |
29 March 22 |
Dividend/Distribution - SIG
×
Dividend/Distribution - SIG |
29 March 11 |
Amendment to Results Presentation (SIP-AU)
×
Amendment to Results Presentation (SIP-AU) |
29 December 21 |
Appendix 3Y Change of Directors Interest notices
×
Appendix 3Y Change of Directors Interest notices |
28 March 11 |
Sigma Pharmaceuticals Limited - Results Presentation for the full year ended 31 January 2011 (SIP-AU)
×
Sigma Pharmaceuticals Limited - Results Presentation for the full year ended 31 January 2011 (SIP-AU) |
28 June 22 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
28 June 22 |
Ceasing to be a substantial holder from CBA
×
Ceasing to be a substantial holder from CBA |
27 March 14 |
Sigma Pharmaceuticals Limited - Sigma 2013/14 Full Year Results Presentation (SIP-AU)
×
Sigma Pharmaceuticals Limited - Sigma 2013/14 Full Year Results Presentation (SIP-AU) |
27 June 22 |
Notice of initial substantial holder - HMC Capital Partners
×
Notice of initial substantial holder - HMC Capital Partners |
27 June 22 |
Change in substantial holding
×
Change in substantial holding |
27 June 22 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
27 July 23 |
Appointment of CFO
×
Appointment of CFO |
26 September 22 |
Half Yearly Report and Accounts
×
Half Yearly Report and Accounts |
26 September 22 |
Half Year Results
×
Half Year Results |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Upload your portfolio and gain access to 3-year dividend forecasts for each holding with HALO Global. Empower your decision-making and maximize returns with our advanced analytical tool. Try it today.
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.